多肽类药物的发展及其在制剂学上的难点  

On the Development of Peptide Drugs and Its Difficulties in Pharmaceutics

作　　者：何飞腾 HE Feiteng(Hunan Agricultural University Changsha,Hunan 410125)

机构地区：[1]湖南农业大学,湖南长沙410125

出　　处：《工业微生物》2023年第2期92-94,共3页Industrial Microbiology

摘　　要：近些年,随着多肽合成工艺逐步成熟和药物制剂技术不断提升,多肽类药物受到国内、外研究者的广泛关注,与之有关的研发工作陆续展开。临床医学中,多肽类药物主要用于治疗肿瘤、糖尿病、骨质疏松症等多种复杂疾病,应用价值较高。在健康理念越来越受到人们重视之际,摸清多肽类药物当前的发展现状是非常有必要的,并且要对制剂学上暴露的问题展开探究,这是文章研究的重点,最后对多肽类药物制剂的研究进行展望,提出的观点、阐述的策略仅供参考。In recent years,peptide drugs have attracted a lot of attention at home and abroad,and the research and development work related to them has been carried out continuously,with the gradual maturity of peptide synthesis process and the high promotion of pharmaceutical preparation technology.In clinical practice,polypeptide drugs are mainly used to treat multiple complex diseases such as tumor,diabetes,osteoporosis,etc.,with high application value.When the health concept is deeply rooted in people's hearts,it is necessary to find out the current development status of polypeptide drugs and explore the problems exposed in pharmaceutics.This is the focus of this study.Finally,the research of polypeptide drugs is prospected,and the ideas and strategies proposed are for reference only.

关 键 词：多肽类药物 制剂 难点 

分 类 号：R943[医药卫生—药剂学]